Get started
Author

Uluğ Mutlu Günaydın

Observed names: Mutlu Gunaydin Ulug, U. Gunaydin, U. Mutlu Günaydın, U.M. Gunaydin, Ulug Gunaydin, Ulug M. Gunaydin, Ulug Mutlu Gunaydin
OpenAlex ID: A5000515404
Oncologist Burnout Syndrome in Eastern Europe: Results of the Multinational Survey
2020 · Davor Kust, Jure Murgic, et al. · JCO Oncology Practice · 21
Real-world outcomes of pazopanib in metastatic soft tissue sarcoma: a retrospective Turkish oncology group (TOG) study
2023 · Ahmet Bilici, Sinan Koca, et al. · Journal of Cancer Research and Clinical Oncology · 8
PDF
The role of Endocan as a Prognostic Biomarker in community-acquired pneumonia
2019 · Şenay Günaydın, Mehmet Küçük, et al. · Pakistan Journal of Medical Sciences · 8
PDF
Factors associated with delayed diagnosis and treatment in patients with cancer.
2018 · Ilker Nihat Okten, Bilge Aktas Sezen, et al. · Journal of Clinical Oncology · 8
A global phase 2/3, randomized, open-label trial of BNT327/PM8002 in combination with chemotherapy (chemo) in first-line (1L) non-small cell lung cancer (NSCLC).
2025 · Solange Peters, Stephen V. Liu, et al. · Journal of Clinical Oncology · 7
PDF
Oncologist burnout syndrome in Eastern Europe: Results of the multinational survey
2020 · Kust Davor, Murgić Jure, et al. · Zenodo (CERN European Organization for Nuclear Research) · 5
Phase 2 data from ROSETTA Lung-02, a global randomized phase 2/3 trial of pumitamig (PD-L1 × VEGF-A bsAb) + chemotherapy in 1L NSCLC.
2026 · Solange Peters, Youngjoo Lee, et al. · Journal of Clinical Oncology · 4
PDF
Total Lesion Glycolysis Obtained by FDG PET/CT in Diagnosing Solitary Pulmonary Nodules
2023 · Serkan Gungor, Ulug Mutlu Gunaydin, et al. · Journal of College of Physicians And Surgeons Pakistan · 4
PDF
Neoadjuvant treatment in patients with locally advanced gastric cancer.
2019 · Mahmut Gumus, Serap Kaya, et al. · Journal of Clinical Oncology · 3
Real life data from Turkey regarding the impact of first-line sunitinib and pazopanib in metastatic renal cell cancer.
2019 · Ulas Isik, Osman Kostek, et al. · Journal of Clinical Oncology · 2
Analysis of feasibility of geriatric assessment tools in elderly cancer patients and effects on anti-cancer treatment planning.
2018 · Ulug Mutlu Gunaydin, Asli Tufan Cincin, et al. · Journal of Clinical Oncology · 2
69P First-line pumitamig (PD-L1 × VEGF-A bsAb) monotherapy in PD-L1+ non-squamous and squamous non-small cell lung cancer: Data from a phase Ib/IIa trial in China
2026 · L. Zhang, D. Lv, et al. · ESMO Open · 1
PDF
Abstract CT207: A phase 1 open-label, dose escalation and expansion trial to investigate the safety, pharmacokinetics and pharmacodynamics of CB307, a Trispecific Humabody® T-cell enhancer, in patients with PSMA+ advanced and/or metastatic solid tumors (POTENTIA)
2022 · Johann S. de Bono, Hendrik-Tobias Arkenau, et al. · Cancer Research · 1
PP01.58: A Global Phase 2/3, Randomized, Open-Label Trial of Pumitamig (BNT327/BMS986545; PD-L1 × VEGF-A bsAb) in Combination with Chemotherapy in First-Line (1L) Non-Small Cell Lung Cancer (NSCLC) – ROSETTA Lung-02
2026 · Solange Peters, Stephen V. Liu, et al. · Journal of Thoracic Oncology
149TiP ROSETTA Lung-02: A global phase II/III, randomized, open-label trial of pumitamig, a PD-L1 × VEGF-A bispecific antibody, in combination with chemotherapy in patients (pts) with first-line non-small cell lung cancer
2026 · S. Peters, Y. Lee, et al. · ESMO Open
Evaluation of membrane type 1 metalloproteinase (MT1-MMP/MMP14) expression as a prognostic biomarker in patients with solid tumours screened for a Phase I/II trial
2022 · N. Peters, H. Morley, et al. · European Journal of Cancer
PDF
Is docetaxel-free interval a predictive factor for castration-resistant prostate cancer?
2022 · S. Ay, Ö. Efiloğlu, et al. · Actas Urológicas Españolas (English Edition)
¿Es el intervalo libre de docetaxel un factor predictivo para el cáncer de próstata resistente a la castración?
2022 · S. Ay, Ö. Efiloğlu, et al. · Actas Urológicas Españolas
Works count: 18
Citation count: 74
H-index: 5
I10-index: 1
Year
Topic
Type